CD8A and neoplasm: Given the critical role of CD8 T cells in anti-tumor immunity, we employed a mouse SCC model, where tumor-bearing recipients diverged into responders vs. non-responders upon anti-PD-L1 treatment, to examine the contribution of CD8 T cells to differential responses to ICI (19).